{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.5","upperLimit":"82.0","value":"64.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"12 cycles","title":"Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}